A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

Inclusion Criteria * Age (informed consent): \>=20 years of age * Dialysis: On HD or hemodiafiltration (HDF) given three times weekly for at least 12 weeks prior to screening * ESAs: Use of one and the same ESA for 10 weeks prior to screening * ESA dose: Darbepoetin alfa 10 to 60 μg per week, epoetin (including biosimilars) \<=9000 international units (IU) per week, or epoetin beta pegol \<=250 μg per 4 weeks * Hgb:\>=9.5 g/dL and \<=12.5 g/dL. Determined at the site using an Hgb analyzer * Iron parameters: Ferritin \>100 nanogram (ng)/millilitre (mL) or transferrin saturation (TSAT) \>20 percent (screening verification only) * Gender (screening verification only): Female or male Females: Not pregnant \[demonstrated to be negative for human chorionic gonadotropin (hCG) in serum\], not breast-feeding, and meet at least one of the following: • Females of non-childbearing potential are defined as follows: Pre-menopausal with at least one of the following and no plans to utilise assisted reproductive techniques (e.g., in vitro fertilisation or donor embryo transfer): * History of bilateral tubal ligation or salpingectomy * History of hysteroscopic tubal occlusion and postoperatively documented bilateral tubal obstruction * History of hysterectomy * History of bilateral oophorectomy Postmenopausal defined as A) females 60 years of age or older or B) In females \< 60 years of age, 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with postmenopausal fo…